Market Research Logo

Cancer Supportive Care Products Market to 2016 - Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars

Cancer Supportive Care Products Market to 2016 - Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars

Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Cancer Supportive Care Products Market to 2016 - Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars”, which provides insights into the cancer supportive care products market and forecasts until 2016. The report provides an in-depth analysis of the six major cancer supportive care products indications, which are oral mucositis and dry mouth, chemotherapy-induced nausea and vomiting, cancer pain, chemotherapy-induced anemia, chemotherapy-induced neutropenia and bone metastases. The report also looks into the major unmet needs in the cancer supportive care products market and the major classes of drugs that treat the indications covered in the sector. The report also analyzes the key drivers and restraints that are expected to impact each of the indications in the global cancer supportive care products market. The report also delves into the cancer supportive care products market in the top seven countries in the world, which includes the US, the UK, Germany, France, Italy, Spain and Japan. In addition, the report also includes insights into the R&D (Research & Development) pipeline for the six cancer supportive care indications. In addition, the report also looks into the major M&A (Mergers & Acquisitions) and licensing deals that have taken place between 2008 and 2010 in the global cancer supportive care products market space.

Scope

The scope of this report includes -

  • Data and analysis on the cancer supportive care products market.
  • Annualized market data for the cancer supportive care products market from 2001 to 2009, with forecasts to 2016.
  • Market data on the therapeutic landscape which covers oral mucositis and dry mouth, chemotherapy-induced nausea and vomiting, cancer pain, chemotherapy-induced anemia, chemotherapy-induced neutropenia and bone metastases, including market size, market share, annual cost of therapy, treatment usage patterns such as prevalence population and prescription population.
  • Key drivers and restraints that have had a significant impact on the market and on each indication.
  • The geographic landscape that covers the US, the top five countries of Europe (the UK, France, Germany, Spain and Italy) and Japan.
  • The competitive landscape of the cancer supportive care products market which includes companies such as Amgen, Johnson & Johnson, Roche, Novartis and Pfizer
  • Key M&A activities and Licensing Agreements that took place from 2008 to 2010 in the cancer supportive care products market.
Reasons to buy

The report will enhance your decision making capability. It will allow you to -
  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the leading countries and therapeutic segments poised for strong growth.
  • Devise a more tailored country strategy through the understanding of key drivers and barriers of each region’s pharmaceutical market.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.


GBI Research, the leading business intelligence provider, has released its latest research, “Cancer Supportive Care Products Market to 2016 - Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars”, which provides insights into the cancer supportive care products market and forecasts until 2016. The report provides an in-depth analysis of the six major cancer supportive care products indications, which are oral mucositis and dry mouth, chemotherapy-induced nausea and vomiting, cancer pain, chemotherapy-induced anemia, chemotherapy-induced neutropenia and bone metastases. The report also looks into the major unmet needs in the cancer supportive care products market and the major classes of drugs that treat the indications covered in the sector. The report also analyzes the key drivers and restraints that are expected to impact each of the indications in the global cancer supportive care products market. The report also delves into the cancer supportive care products market in the top seven countries in the world, which includes the US, the UK, Germany, France, Italy, Spain and Japan. In addition, the report also includes insights into the R&D (Research & Development) pipeline for the six cancer supportive care indications. In addition, the report also looks into the major M&A (Mergers & Acquisitions) and licensing deals that have taken place between 2008 and 2010 in the global cancer supportive care products market space.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

The Global Cancer Supportive Care Products Market is Expected to Witness Sluggish Annual Growth of 2% between 2009 and 2016

In 2009, the global cancer supportive care products market was valued at $11 billion, up from $7.5 billion in 2001, indicating a CAGR (Compounded Annual Growth Rate) of 5% between 2001 and 2009. The major drivers of the growth had been the launch of new and better treatment medications, increased prevalence of cancer and a resulting increase in chemotherapy patient populations.

Cancer Supportive Care Products Market, Global, Revenue Forecast ($m), 2001-2016

Source: GBI Research, Company Websites, American Society of Clinical Oncology, Journal of European Society for Therapeutic Radiology and Oncology, National Cancer Institute

In future, the global cancer supportive care products market is expected to reach $12.6 billion, indicating a CAGR of 2% during the period 2009-2016. The market will grow until 2014 at a growth rate of approximately 3- 5%, followed by a decline of approximately 1.2% until 2016 due to the patent expiry of leading drugs across all major markets. Some of the major drugs that are expected to lose patent protection between 2013 and 2016 include Neupogen (filgrastim), Neulasta (pegfilgrastim), Aranesp (darbepoetin alfa), Procrit (epoetin alfa), Emend (aprepitant), Zometa (zoledronic acid) and Aloxi (palonosetron hydrochloride). Thus, patent expiries coupled with a weak development pipeline will be the major factors behind the sluggish growth of the cancer supportive care products market in future.

Growth in the Bone Metastases, Oral Mucositis and Dry Mouth, and Cancer Pain Markets will Drive the Future Market Growth

Bone metastases, oral mucositis and dry mouth, and cancer pain therapeutics are the sectors estimated to demonstrate significant growth in future among all the segments of the global cancer supportive care products market. Between 2009 and 2016, the bone metastases therapeutics market will be the fastest growing market segment, and is expected to reach $1.2 billion in 2016 from $690m in 2009, indicating a CAGR of 8.1%. Increased uptake of novel monoclonal antibody, Xgeva (denosumab), which received approval for bone metastases in cancer patients in November 2010, is expected to be the principal driver for the market. In addition, an increasing prevalence population is also expected to drive the market in future. On the other hand, the oral mucositis and dry mouth therapeutics market is expected to witness a CAGR of 5.9% between 2009 and 2016 to reach $2.1 billion in 2016 from $1.4 billion in 2009. High unmet need in terms of efficacious drugs and the increasing prevalence of the disease are expected to be the major drivers of the global oral mucositis and dry mouth therapeutics market in future. The cancer pain therapeutics market will witness a CAGR of 5.3% between 2009 and 2016, driven by increasing prescription rates and new modes of delivery of cancer pain drugs that will help in the better management of pain for a longer duration. These factors are expected to drive the global cancer pain therapeutics market from $2 billion in 2009 to $2.9 billion in 2016.

Weak Pipeline with Very Few Promising Molecules Will Lead to Increased Dominance of Biosimilars in the Market after the Patent Expiry of Leading Biologics

The current cancer supportive care therapeutics pipeline is weak, with very few promising molecules in the late stages of development. In terms of phases, Phase III accounts for approximately one-third of the global cancer supportive care pipeline, while Phase II molecules account for 39%. Four compounds are in the regulatory filing stage. However, a large majority of these drugs are either me-too, combination therapies of existing drugs, or new formulations. Therefore, in spite of having 38% of the pipeline in the late stages of drug development, the cancer supportive care products market is not expected to witness any major drug launches in the near future. In the entire pipeline, there are only five to six major novel promising compounds, a scenario which does not suggest strong future market growth.

Thus, the weak development pipeline is expected to be one of the major factors that are expected to restrict the growth of the future cancer supportive care products market.

Emerging Pharmaceutical Geographies Dominate As Areas of Concentration in the M&A and Licensing Deals for Cancer Supportive Care Products Market

Cancer Supportive Care, Global, M&A and Licensing Agreements by Geography, 2008-2010

Source: GBI Research, GBI Research’s Internal Database, Company Websites, Press Releases

Between 2008 and 2010, a significant majority of the M&A (Mergers & Acquisitions) and licensing deals concentrated on emerging geographies such as Asia-Pacific, MEA (Middle East and Africa) and SCA (South and Central America). Asia-Pacific was one of the regions of concentration in 55% of the total number of deals. On the other hand, MEA and SCA each formed part of 18% of the deals. A total of 39% of the deals had North America as their geographic concentration, while only 20% of the deals concentrated on Europe.

Thus, in future, emerging geographies are expected to dominate as the major areas of focus for the pharmaceutical companies when it comes to M&A and licensing agreements. One of the major reasons for this is expected to be the leading companies’ strategies of expanding into newer markets with their existing products. Also, through partnering with generic companies in the developing geographies to market their product the pharmaceutical companies expect to gain greater market share in the generics-dominated markets of these regions.

  • Executive Summary
    • Table Figure 1: Cancer Supportive Care Products Market, Global, Revenue Forecast ($m), 2001-2016
    • Table Figure 2: Cancer Supportive Care, Global, M&A and Licensing Agreements by Geography, 2008–2010
  • Cancer Supportive Care Products Market: Introduction
    • GBI Research Report Guidance
  • Cancer Supportive Care Products Market: Market Overview
    • Revenue
      • Table Figure 3: Cancer Supportive Care Products Market, Global, Revenue Forecast ($m), 2001–2016
      • Table Cancer Supportive Care Products Market, Global, Revenue ($m), 2001–2009
      • Table Cancer Supportive Care Products Market, Global, Revenue Forecast ($m), 2009–2016
    • Average Annual Cost of Therapy
      • Table Figure 4: Cancer Supportive Care Products Market, Global, Average Annual Cost of Therapy ($), 2001–2016
      • Table Cancer Supportive Care Products Market, Global, Average Annual Cost of Therapy ($), 2001–2009
      • Table Cancer Supportive Care Products Market, Global, Average Annual Cost of Therapy ($), 2009–2016
    • Therapeutic Segmentation
      • Table Figure 5: Cancer Supportive Care Products Market, Global, Market Share by Indication (%), 2009 and 2016
    • Geographic Segmentation
      • Table Figure 6: Cancer Supportive Care Products Market, Geographical Segmentation, Revenue ($m), 2001–2016
      • Table Cancer Supportive Care Products Market, Geographical Segmentation, Revenue ($m), 2001–2009
      • Table Cancer Supportive Care Products Market, Geographical Segmentation, Revenue ($m), 2009–2016
      • Table Figure 7: Cancer Supportive Care Products Market, Market Share by Geography (%), 2009 and 2016
      • Table Figure 8: Cancer Supportive Care Products Market, Market Share of the Top Five Countries of Europe (%), 2009 and 2016
    • Generic Share in the Cancer Supportive Care Products Market
      • Table Figure 9: Cancer Supportive Care Products Market, Sales of Generics Versus Branded Drugs ($m), 2001-2016
      • Table Cancer Supportive Care Products Market, Sales of Generics Versus Branded Drugs ($m), 2001-2009
      • Table Cancer Supportive Care Products Market, Sales of Generics Versus Branded Drugs ($m), 2009-2016
    • Drivers and Restraints of Cancer Supportive Care Products Market
      • Drivers
      • Restraints
    • Unmet Needs
      • Efficacy
      • Safety
      • Price
    • Major Drug Classes
      • Anti-infectives (Oral Mucositis)
      • Anti-emetics (CINV)
      • Bisphosphonates (Bone Metastases)
      • Erythropoietin Stimulating Agents (CIA)
      • Granulocyte Colony Stimulating Factors (CINP)
      • Opioid Analgesics (Cancer Pain and Bone Metastases)
      • NSAIDs (Cancer Pain and Bone Metastases)
      • Monoclonal Antibodies (Bone Metastases)
  • Cancer Supportive Care Products Market: Therapeutic Landscape
    • Oral Mucositis and Dry Mouth Market
      • Introduction
        • Table Figure 10: Oral Mucositis and Dry Mouth, World Health Organization Toxicity-based Classification for Oral Mucositis, 2011
      • Revenue
        • Table Figure 11: Oral Mucositis and Dry Mouth, Global, Revenue Forecast ($m), 2001–2016
        • Table Oral Mucositis and Dry Mouth, Global, Revenue ($m), 2001–2009
        • Table Oral Mucositis and Dry Mouth, Global, Revenue Forecast ($m), 2009–2016
      • Annual Cost of Therapy
        • Table Figure 12: Oral Mucositis and Dry Mouth, Global, Annual Cost of Therapy ($), 2001–2016
        • Table Oral Mucositis and Dry Mouth, Global, Annual Cost of Therapy ($), 2001–2009
        • Table Oral Mucositis and Dry Mouth, Global, Annual Cost of Therapy ($), 2009–2016
      • Treatment Usage Patterns
        • Table Figure 13: Oral Mucositis and Dry Mouth, Global, Treatment Usage Pattern (‘000), 2001–2016
        • Table Oral Mucositis and Dry Mouth, Global, Treatment Usage Pattern (‘000), 2001–2009
        • Table Oral Mucositis and Dry Mouth, Global, Treatment Usage Pattern (‘000), 2009–2016
        • Table Figure 14: Oral Mucositis and Dry Mouth, Global, Prevalence Population (‘000), 2001–2016
        • Table Figure 15: Oral Mucositis and Dry Mouth, Global, Prescription Population (‘000), 2001–2016
      • Drivers for the Oral Mucositis and Dry Mouth Market
      • Restraints for the Oral Mucositis and Dry Mouth Market
      • Geographical Segmentation
        • Table Figure 16: Oral Mucositis and Dry Mouth, Geographical Segmentation, Revenue ($m), 2001–2016
        • Table Oral Mucositis and Dry Mouth, Geographical Segmentation, Revenue ($m), 2001–2009
        • Table Oral Mucositis and Dry Mouth, Geographical Segmentation, Revenue ($m), 2009–2016
        • Table Figure 17: Oral Mucositis and Dry Mouth, Market Share by Geography (%), 2009 and 2016
        • Table Figure 18: Oral Mucositis and Dry Mouth, Market Share of Top Five Countries of Europe (%), 2009 and 2016
    • Chemotherapy Induced Nausea and Vomiting Market
      • Introduction
        • Table Figure 19: Chemotherapy Induced Nausea and Vomiting, Classification and Risk Factors, 2011
        • Table Chemotherapy Induced Nausea and Vomiting, Emetic Risk Levels of Major Chemotherapeutic Agents
      • Revenue
        • Table Figure 20: Chemotherapy Induced Nausea and Vomiting, Global, Revenue Forecast ($m), 2001–2016
        • Table Chemotherapy Induced Nausea and Vomiting, Global, Revenue ($m), 2001–2009
        • Table Chemotherapy Induced Nausea and Vomiting, Global, Revenue Forecast ($m), 2009–2016
      • Annual Cost of Therapy
        • Table Figure 21: Chemotherapy Induced Nausea and Vomiting, Global, Annual Cost of Therapy ($), 2001–2016
        • Table Chemotherapy Induced Nausea and Vomiting, Global, Annual Cost of Therapy ($), 2001–2009
        • Table Chemotherapy Induced Nausea and Vomiting, Global, Annual Cost of Therapy ($), 2009–2016
      • Treatment Usage Patterns
        • Table Figure 22: Chemotherapy Induced Nausea and Vomiting, Global, Treatment Usage Pattern (‘000), 2001–2016
        • Table Chemotherapy Induced Nausea and Vomiting, Global, Treatment Usage Pattern (‘000), 2001–2009
        • Table Chemotherapy Induced Nausea and Vomiting, Global, Treatment Usage Pattern (‘000), 2009–2016
        • Table Figure 23: Chemotherapy Induced Nausea and Vomiting, Global, Prevalence Population (‘000), 2001–2016
        • Table Figure 24: Chemotherapy Induced Nausea and Vomiting, Global, Prescription Population (‘000), 2001–2016
      • Drivers for the Chemotherapy Induced Nausea and Vomiting Market
      • Restraints for the Chemotherapy Induced Nausea and Vomiting Market
      • Geographical Landscape
        • Table Figure 25: Chemotherapy Induced Nausea and Vomiting, Geographical Segmentation, Revenue ($m), 2001–2016
        • Table Chemotherapy Induced Nausea and Vomiting, Geographical Segmentation, Revenue ($m), 2001–2009
        • Table Chemotherapy Induced Nausea and Vomiting, Geographical Segmentation, Revenue ($m), 2009–2016
        • Table Figure 26: Chemotherapy Induced Nausea and Vomiting, Market Share by Geography (%), 2009 and 2016
        • Table Figure 27: Chemotherapy Induced Nausea and Vomiting, Market Share of Top Five Countries of Europe (%), 2009 and 2016
    • Cancer Pain Market
      • Introduction
      • Revenue
        • Table Figure 28: Cancer Pain, Global, Revenue Forecast ($m), 2001–2016
        • Table Cancer Pain, Global, Revenue ($m), 2001–2009
        • Table Cancer Pain, Global, Revenue Forecast ($m), 2009–2016
      • Annual Cost of Therapy
        • Table Figure 29: Cancer Pain, Global, Annual Cost of Therapy ($), 2001-2016
        • Table Cancer Pain, Global, Annual Cost of Therapy ($), 2001-2009
        • Table Cancer Pain, Global, Annual Cost of Therapy ($), 2009-2016
      • Treatment Usage Patterns
        • Table Figure 30: Cancer Pain, Global, Treatment Usage Patterns (‘000), 2001-2016
        • Table Cancer Pain, Global, Treatment Usage Patterns (‘000), 2001-2009
        • Table Cancer Pain, Global, Treatment Usage Patterns (‘000), 2009-2016
        • Table Figure 31: Cancer Pain, Global, Prevalence Population (‘000), 2001-2016
        • Table Figure 32: Cancer Pain, Global, Treatment Seeking Population (‘000), 2001-2016
        • Table Figure 33: Cancer Pain, Global, Diagnosed Population (‘000), 2001-2016
        • Table Figure 34: Cancer Pain, Global, Prescription Population (‘000), 2001-2016
      • Drivers for the Cancer Pain Market
      • Restraints for the Cancer Pain Market
      • Geographical Landscape
        • Table Figure 35: Cancer Pain, Geographical Segmentation, Revenue ($m), 2001–2016
        • Table Cancer Pain, Geographical Segmentation, Revenue ($m), 2001–2009
        • Table Cancer Pain, Geographical Segmentation, Revenue ($m), 2009–2016
        • Table Figure 36: Cancer Pain, Market Share by Geography (%), 2009 and 2016
        • Table Figure 37: Cancer Pain, Market Share of Top Five Countries of Europe (%), 2009 and 2016
    • Chemotherapy Induced Anemia Market
      • Introduction
      • Revenue
        • Table Figure 38: Chemotherapy Induced Anemia, Global, Revenue Forecast ($m), 2001–2016
        • Table Chemotherapy Induced Anemia, Global, Revenue ($m), 2001–2009
        • Table Chemotherapy Induced Anemia, Global, Revenue Forecast ($m), 2009–2016
      • Annual Cost of Therapy
        • Table Figure 39: Chemotherapy Induced Anemia, Global, Annual Cost of Therapy ($), 2001–2016
        • Table Chemotherapy Induced Anemia, Global, Annual Cost of Therapy ($), 2001–2009
        • Table Chemotherapy Induced Anemia, Global, Annual Cost of Therapy ($), 2009–2016
      • Treatment Usage Patterns
        • Table Figure 40: Chemotherapy Induced Anemia, Global, Treatment Usage Pattern (‘000), 2001–2016
        • Table Chemotherapy Induced Anemia, Global, Treatment Usage Pattern (‘000), 2001–2009
        • Table Chemotherapy Induced Anemia, Global, Treatment Usage Pattern (‘000), 2009–2016
        • Table Figure 41: Chemotherapy Induced Anemia, Global, Prevalence Population (‘000), 2001–2016
        • Table Figure 42: Chemotherapy Induced Anemia, Global, Prescription Population (‘000), 2001–2016
      • Drivers for the Chemotherapy Induced Anemia Market
      • Restraints for the Chemotherapy Induced Anemia Market
      • Geographical Landscape
        • Table Figure 43: Chemotherapy Induced Anemia, Geographical Segmentation, Revenue ($m), 2001–2016
        • Table Chemotherapy Induced Anemia, Geographical Segmentation, Revenue ($m), 2001–2009
        • Table Chemotherapy Induced Anemia, Geographical Segmentation, Revenue ($m), 2009–2016
        • Table Figure 44: Chemotherapy Induced Anemia, Market Share by Geography (%), 2009 and 2016
        • Table Figure 45: Chemotherapy Induced Anemia, Market Share of Top Five Countries of Europe (%), 2009 and 2016
    • Chemotherapy Induced Neutropenia Market
      • Introduction
        • Table Figure 46: Chemotherapy Induced Neutropenia, National Cancer Institute’s Common Toxicity Criteria for CINP, 2011
      • Revenue
        • Table Figure 47: Chemotherapy Induced Neutropenia, Global, Revenue Forecast ($m), 2001–2016
        • Table Chemotherapy Induced Neutropenia, Global, Revenue ($m), 2001–2009
        • Table Chemotherapy Induced Neutropenia, Global, Revenue Forecast ($m), 2009–2016
      • Annual Cost of Therapy
        • Table Figure 48: Chemotherapy Induced Neutropenia, Global, Annual Cost of Therapy ($), 2001–2016
        • Table Chemotherapy Induced Neutropenia, Global, Annual Cost of Therapy ($), 2001–2009
        • Table Chemotherapy Induced Neutropenia, Global, Annual Cost of Therapy ($), 2009–2016
      • Treatment Usage Patterns
        • Table Figure 49: Chemotherapy Induced Neutropenia, Global, Treatment Usage Pattern (‘000), 2001–2016
        • Table Chemotherapy Induced Neutropenia, Global, Treatment Usage Pattern (‘000), 2001–2009
        • Table Chemotherapy Induced Neutropenia, Global, Treatment Usage Pattern (‘000), 2009–2016
        • Table Figure 50: Chemotherapy Induced Neutropenia, Global, Prevalence Population (‘000), 2001–2016
        • Table Figure 51: Chemotherapy Induced Neutropenia, Global, Prescription Population (‘000), 2001–2016
      • Drivers for the Chemotherapy Induced Neutropenia Market
      • Restraints for the Chemotherapy Induced Neutropenia Market
      • Geographical Landscape
        • Table Figure 52: Chemotherapy Induced Neutropenia, Geographical Segmentation, Revenue ($m), 2001–2016
        • Table Chemotherapy Induced Neutropenia, Geographical Segmentation, Revenue ($m), 2001–2009
        • Table Chemotherapy Induced Neutropenia, Geographical Segmentation, Revenue ($m), 2009–2016
        • Table Figure 53: Chemotherapy Induced Neutropenia, Market Share by Geography (%), 2009 and 2016
        • Table Figure 54: Chemotherapy Induced Neutropenia, Market Share of Top Five Countries of Europe (%), 2009 and 2016
    • Bone Metastases Market
      • Introduction
      • Revenue
        • Table Figure 55: Bone Metastases, Global, Revenue Forecast ($m), 2001–2016
        • Table Bone Metastases, Global, Revenue ($m), 2001–2009
        • Table Bone Metastases, Global, Revenue Forecast ($m), 2009–2016
      • Annual Cost of Therapy
        • Table Figure 56: Bone Metastases, Global, Annual Cost of Therapy ($), 2001–2016
        • Table Bone Metastases, Global, Annual Cost of Therapy ($), 2001–2009
        • Table Bone Metastases, Global, Annual Cost of Therapy ($), 2009–2016
      • Treatment Usage Patterns
        • Table Figure 57: Bone Metastases, Global, Treatment Usage Pattern (‘000), 2001–2016
        • Table Bone Metastases, Global, Treatment Usage Pattern (‘000), 2001–2009
        • Table Bone Metastases, Global, Treatment Usage Pattern (‘000), 2009–2016
        • Table Figure 58: Bone Metastases, Global, Prevalence Population (‘000), 2001–2016
        • Table Figure 59: Bone Metastases, Global, Prescription Population (‘000), 2001–2016
      • Drivers for the Bone Metastases Market
      • Restraints for the Bone Metastases Market
      • Geographical Landscape
        • Table Figure 60: Bone Metastases, Geographical Segmentation, Revenue ($m), 2001–2016
        • Table Bone Metastases, Geographical Segmentation, Revenue ($m), 2001–2009
        • Table Bone Metastases, Geographical Segmentation, Revenue ($m), 2009–2016
        • Table Figure 61: Bone Metastases, Market Share by Geography (%), 2009 and 2016
        • Table Figure 62: Bone Metastases, Market Share of Top Five Countries of Europe (%), 2009 and 2016
  • Cancer Supportive Care Products Market: Geographical Landscape
    • The US
      • Revenue
        • Table Figure 63: Cancer Supportive Care Products Market, the US, Revenue Forecast ($m), 2001–2016
        • Table Cancer Supportive Care Products Market, the US, Revenue ($m), 2001–2009
        • Table Cancer Supportive Care Products Market, the US, Revenue Forecast ($m), 2009–2016
      • Average Annual Cost of Therapy
        • Table Figure 64: Cancer Supportive Care Products Market, the US, Average Annual Cost of Therapy ($), 2001–2016
        • Table Cancer Supportive Care Products Market, the US, Average Annual Cost of Therapy ($), 2001–2009
        • Table Cancer Supportive Care Products Market, the US, Average Annual Cost of Therapy ($), 2009–2016
      • Therapeutic Segmentation
        • Table Figure 65: Cancer Supportive Care Products Market, the US, Market Share by Indication (%), 2009 and 2016
    • Top Five Countries of Europe
      • Revenue
        • Table Figure 66: Cancer Supportive Care Products Market, Top Five Countries of Europe, Revenue Forecast ($m), 2001–2016
        • Table Cancer Supportive Care Products Market, Top Five Countries of Europe, Revenue ($m), 2001–2009
        • Table Cancer Supportive Care Products Market, Top Five Countries of Europe, Revenue Forecast ($m), 2009–2016
      • Average Annual Cost of Therapy
        • Table Figure 67: Cancer Supportive Care Products Market, Top Five Countries of Europe, Average Annual Cost of Therapy ($), 2001–2016
        • Table Cancer Supportive Care Products Market, Top Five Countries of Europe, Average Annual Cost of Therapy ($), 2001–2009
        • Table Cancer Supportive Care Products Market, Top Five Countries of Europe, Average Annual Cost of Therapy ($), 2009–2016
      • Therapeutic Segmentation
        • Table Figure 68: Cancer Supportive Care Products Market, Top Five Countries of Europe, Market Share by Indication (%), 2009 and 2016
      • Geographic Segmentation
        • Table Figure 69: Cancer Supportive Care Products Market, Top Five Countries of Europe, Market Share by Country (%), 2009 and 2016
    • Japan
      • Revenue
        • Table Figure 70: Cancer Supportive Care Products Market, Japan, Revenue Forecast ($m), 2001–2016
        • Table Cancer Supportive Care Products Market, Japan, Revenue ($m), 2001–2009
        • Table Cancer Supportive Care Products Market, Japan, Revenue Forecast ($m), 2009–2016
      • Average Annual Cost of Therapy
        • Table Figure 71: Cancer Supportive Care Products Market, Japan, Average Annual Cost of Therapy ($), 2001–2016
        • Table Cancer Supportive Care Products Market, Japan, Average Annual Cost of Therapy ($), 2001–2009
        • Table Cancer Supportive Care Products Market, Japan, Average Annual Cost of Therapy ($), 2009–2016
      • Therapeutic Segmentation
        • Table Figure 72: Cancer Supportive Care Products Market, Japan, Market Share by Indication (%), 2009 and 2016
  • Cancer Supportive Care Products Market: Pipeline Analysis
    • Introduction
      • Table Figure 73: Cancer Supportive Care Products, Global, Pipeline by Indication, 2010
      • Table Figure 74: Cancer Supportive Care Products, Global, Pipeline by Phase (%), 2010
      • Research and Development Pipeline – Oral Mucositis and Dry Mouth
        • Table Figure 75: Oral Mucositis and Dry Mouth, Global, Pipeline by Phase (%), 2010
      • Research and Development Pipeline – Chemotherapy Induced Nausea and Vomiting
        • Table Figure 76: Chemotherapy Induced Nausea and Vomiting, Global, Pipeline by Phase (%), 2010
      • Research and Development Pipeline – Cancer Pain
        • Table Figure 77: Cancer Pain, Global, Pipeline by Phase (%), 2010
      • Research and Development Pipeline – Chemotherapy Induced Anemia
        • Table Figure 78: Chemotherapy Induced Anemia, Global, Pipeline by Phase (%), 2010
      • Research and Development Pipeline – Chemotherapy Induced Neutropenia
        • Table Figure 79: Chemotherapy Induced Neutropenia, Global, Pipeline by Phase (%), 2010
      • Research and Development Pipeline – Bone Metastases
        • Table Figure 80: Bone Metastases, Global, Pipeline by Phase (%), 2010
    • Profiles of Promising Drugs in the Cancer Supportive Care Products Market
      • Xgeva/Prolia (denosumab) – Bone Metastases
      • Alpharadin – Bone Metastases
      • MAXY-G34 – Chemotherapy Induced Neutropenia
      • Lactermin – Oral Mucositis
      • Xen2174 – Cancer Pain
      • Tectin – Cancer Pain
      • NasalFent – Cancer Pain
  • Cancer Supportive Care Products Market: Competitive Landscape
    • Market Share Analysis
      • Table Figure 81: Cancer Supportive Care Products Market, Global, Market Share by Companies (%), 2009
    • Competitive Profiling
      • Amgen
        • Table Cancer Supportive Care Products Market, Global, Pipeline Products – Amgen, 2011
        • Table Figure 82: Cancer Supportive Care Products Market, Amgen SWOT Analysis, 2011
      • Johnson & Johnson
        • Table Cancer Supportive Care Products Market, Global, Pipeline Products – Johnson & Johnson, 2011
        • Table Figure 83: Cancer Supportive Care Products Market, Johnson & Johnson SWOT Analysis, 2011
      • F. Hoffmann-La Roche
        • Table Cancer Supportive Care Products Market, Global, Pipeline Products – F. Hoffmann-La Roche, 2011
        • Table Figure 84: Cancer Supportive Care Products Market, F. Hoffmann-La Roche SWOT Analysis, 2011
      • Novartis
        • Table Cancer Supportive Care Products Market, Global, Pipeline Products – Novartis, 2011
        • Table Figure 85: Cancer Supportive Care Products Market, Novartis SWOT Analysis, 2011
      • Pfizer
        • Table Cancer Supportive Care Products Market, Global, Pipeline Products – Pfizer, 2011
        • Table Figure 86: Cancer Supportive Care Products Market, Pfizer SWOT Analysis, 2011
  • Cancer Supportive Care Products Market: Deals Landscape
    • M&A and Licensing Agreements
      • Deals by Year
        • Table Figure 87: Cancer Supportive Care Products Market, Global, M&A and Licensing Agreements by Year, 2008–2010
      • Deals by Deal Type
        • Table Figure 88: Cancer Supportive Care Products Market, Global, M&As and Licensing Agreements by Deal Type, 2008–2010
      • Deals by Indication
        • Table Figure 89: Cancer Supportive Care Products Market, Global, M&As and Licensing Agreements by Indication, 2008–2010
      • Deals by Value ($m)
        • Table Figure 90: Cancer Supportive Care Products Market, Global, M&As and Licensing Agreements by Deal Value, 2008–2010
      • Deals by Geography
        • Table Figure 91: Cancer Supportive Care Products Market, Global, M&As and Licensing Agreements by Geography, 2008–2010
      • Major Acquisitions in the Cancer Supportive Care Products Market
      • Major Licensing Agreements in the Cancer Supportive Care Products Market
  • Cancer Supportive Care Products Market: Appendix
    • Market Definitions
    • Abbreviations
    • Research Methodology
      • Coverage
      • Primary Research
      • Forecasts
        • Table Figure 92: GBI Research Market Forecasting Model
      • Expert Panel Validation
    • Contact Us
    • Disclaimer
    • Sources

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report